Shih et al. established this regarding 33% of patients with MDS acquiring the FLT3 or NRAS gene mutations during progression to AML [80], and once the patients with these anomalies developed secondary AML, the prognostic was directly correlated with the VAF. The gene discussed is FLT3; the disease is myelodysplastic syndrome.